Cytosorbents Corporation

NasdaqCM:CTSO Stock Report

Market Cap: US$50.5m

Cytosorbents Management

Management criteria checks 3/4

Cytosorbents' CEO is Phil Chan, appointed in Jan 2009, has a tenure of 15.17 years. total yearly compensation is $1.11M, comprised of 43.6% salary and 56.4% bonuses, including company stock and options. directly owns 1.36% of the company’s shares, worth $687.54K. The average tenure of the management team and the board of directors is 3.8 years and 9.5 years respectively.

Key information

Phil Chan

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage43.6%
CEO tenure15.2yrs
CEO ownership1.4%
Management average tenure3.8yrs
Board average tenure9.5yrs

Recent management updates

Recent updates

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Mar 16
Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper

Jan 06
Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper

Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

Nov 10
Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price

Jul 13
Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

May 16
Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Mar 08
We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

CytoSorbents secures $4.3M contract by U.S. Department of Defense

Oct 06

CytoSorbents stock rises on US DoD contract to develop device for universal plasma

Sep 09

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Sep 02
We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

CytoSorbents gets reimbursement for CytoSorb in Turkey

Aug 23

CytoSorbents stock rises 10% as Israel approves coverage for CytoSorb system

Aug 17

Cytosorbents GAAP EPS of -$0.25 misses by $0.13, revenue of $8.5M misses by $1.06M

Aug 02

We're Not Very Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Mar 03
We're Not Very Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

CEO Compensation Analysis

How has Phil Chan's remuneration changed compared to Cytosorbents's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$29m

Sep 30 2023n/an/a

-US$23m

Jun 30 2023n/an/a

-US$26m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$1mUS$483k

-US$33m

Sep 30 2022n/an/a

-US$41m

Jun 30 2022n/an/a

-US$36m

Mar 31 2022n/an/a

-US$29m

Dec 31 2021US$2mUS$483k

-US$25m

Sep 30 2021n/an/a

-US$16m

Jun 30 2021n/an/a

-US$10m

Mar 31 2021n/an/a

-US$9m

Dec 31 2020US$1mUS$456k

-US$8m

Sep 30 2020n/an/a

-US$11m

Jun 30 2020n/an/a

-US$17m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$1mUS$438k

-US$19m

Sep 30 2019n/an/a

-US$21m

Jun 30 2019n/an/a

-US$17m

Mar 31 2019n/an/a

-US$19m

Dec 31 2018US$1mUS$400k

-US$17m

Sep 30 2018n/an/a

-US$15m

Jun 30 2018n/an/a

-US$14m

Mar 31 2018n/an/a

-US$10m

Dec 31 2017US$828kUS$378k

-US$9m

Compensation vs Market: Phil's total compensation ($USD1.11M) is above average for companies of similar size in the US market ($USD658.28K).

Compensation vs Earnings: Phil's compensation has been consistent with company performance over the past year.


CEO

Phil Chan (53 yo)

15.2yrs

Tenure

US$1,106,612

Compensation

Dr. Phillip P. Chan, M.D., Ph D., is known as Phil has been the Chief Executive Officer at Cytosorbents Corporation since January 2009 and served as its President until May 2020. Dr. Chan serves as a Partn...


Leadership Team

NamePositionTenureCompensationOwnership
Phillip Chan
CEO & Director15.2yrsUS$1.11m1.36%
$ 687.5k
Vincent Capponi
President & COO18.7yrsUS$985.94k0.52%
$ 261.4k
Kathleen Bloch
Chief Financial Officerless than a yearUS$847.83k0.46%
$ 230.6k
Efthymios Deliargyris
Chief Medical Officer3.8yrsUS$1.01m0.15%
$ 75.4k
Terri Powers
Vice President of Investor Relations & Corporate Communications2.8yrsno datano data
Christian Steiner
Executive Vice President of Sales & Marketing11.8yrsno datano data
Christopher Cramer
Senior Vice President of Business Development1.2yrsno datano data
Irina Kulinets
Senior Vice President of Global Regulatory Affairs1.2yrsno datano data
Jodi Hoover
Executiveno datano datano data
Robert Bartlett
Co-Chairman of Cardiac Surgery Advisory Board & Consultant6.8yrsUS$97.32kno data

3.8yrs

Average Tenure

66.5yo

Average Age

Experienced Management: CTSO's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Phillip Chan
CEO & Director15.7yrsUS$1.11m1.36%
$ 687.5k
Robert Bartlett
Co-Chairman of Cardiac Surgery Advisory Board & Consultant9.5yrsUS$97.32kno data
Claudio Ronco
Member of Critical Care Advisory Boardno datano datano data
Alan Sobel
Independent Director9.3yrsUS$87.56k0.064%
$ 32.1k
Edward Jones
Independent Director16.9yrsUS$74.33k0.036%
$ 18.2k
Joseph Parrillo
Member of Critical Care Advisory Boardno datano datano data
Ronald Maier
Chairman of the Trauma Advisory Board10.9yrsno datano data
Mitchell Cohen
Member of Trauma Advisory Boardno datano datano data
Ernest Moore
Member of Trauma Advisory Board10.9yrsno datano data
Joseph Zwischenberger
Chairman of Cardiac Surgery Advisory Board9.5yrsno datano data
Jonathan Haft
Member of Cardiac Surgery Advisory Board9.5yrsno datano data
Michael Bator
Independent Chairman of the Board8.7yrsUS$74.33k0.10%
$ 52.2k

9.5yrs

Average Tenure

62yo

Average Age

Experienced Board: CTSO's board of directors are considered experienced (9.5 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.